Authors: Christoph Barth, Elisha Kemp, Stephanie Coleman
The new EU Foreign Direct Investment Screening Regulation (EU 2026/1386) entered into force last week. With it, the 18-month clock starts ticking: Member States have until 17 January 2028 to bring their national FDI frameworks into line with binding new minimum requirements — and several are already moving. Much of what the Regulation introduces has been in the public domain since the political agreement reached in December 2025. What has received less attention is where the final published text went further than the earlier coverage suggested, and what that means for deal teams planning transactions right now.
By now, most practitioners will have read at least one overview of the reform. This post cuts through the accumulated commentary to focus on the provisions of the final text that are most likely to matter in practice — including several that have attracted less attention than they deserve, and some that go meaningfully further than what most readers will have taken away from the earlier coverage.
What’s New and What It Means in Practice
Mandatory prior authorisation
In practice, all 27 Member States already operate national FDI screening mechanisms — Cyprus, the last to act, brought its regime into force in April 2026. The requirement for every Member State to maintain a mandatory screening mechanism is therefore no longer a significant practical shift: the coverage gap had already closed. What the Regulation changes — and what will require meaningful adjustment across virtually all national regimes — is the scope of mandatory prior authorisation. For the first time, Member States must impose a genuine standstill obligation — prohibiting closing without prior authorisation — across a defined set of sensitive sectors: dual-use and defence, semiconductors, quantum technologies, certain AI applications, strategic raw materials, electoral infrastructure, financial market infrastructure, and critical transport, energy and digital infrastructure. Many existing national regimes did not require mandatory pre-closing approval across this full range, or they have applied different definitions and thresholds. That now has to change. Of particular practical note: the dual-use category may catch companies that do not themselves manufacture dual-use goods but source or distribute them commercially — a risk that extends the Regulation’s reach well beyond the defence-adjacent industries that practitioners typically have in mind.
Critical medicines and life sciences — ‘mandatory assessment criteria’
Despite significant momentum during the legislative process, a qualified majority could not be reached in the Council to include life sciences (pharma, biotech and medtech) within the common minimum scope. This means that critical medicines are not a standalone mandatory category, and Member States are not automatically required to screen investments in pharmaceutical companies. However, where a Member State does bring life sciences within its national screening regime it must consider, as a mandatory assessment criterion, whether the target produces a medicine on the Union list of critical medicines. This triggers a compulsory analytical step once a national regime is engaged — but does not independently bring an investment within the harmonised EU-wide minimum scope, as with investments in semiconductors, defence or quantum technologies, and AI.
Clarity on limitations to internal restructuring carve-out
Internal restructurings fall outside the scope of the Regulation — but this is not a blanket safe harbour. The carve-out falls away where a new legal entity established in a third country (i.e. a non-EU country), not already present in the upstream ownership chain of the Union target, is introduced into that chain. The logic is straightforward: if a transaction results in a new third-country entity entering the ownership chain — for example, one subject to legislation requiring it to share information with a foreign government without due process — then the character of the structure has materially changed, and the carve-out should not automatically apply. Transaction planners must therefore map the full upstream ownership chain before relying on this exclusion. Even a routine internal reorganisation can give rise to a filing obligation if it introduces a new third-country entity that was not previously in the chain.
Multi-country transactions: coordinated filings from day one
Where a foreign investment triggers screening obligations in more than one Member State, the final text requires applicants to ‘endeavour’ to file in all relevant Member States on the same day and imposes a mandatory obligation on Member States to coordinate throughout the entire screening procedure — including aligning timelines and ensuring compatibility of any mitigating measures or conditions. This is a (welcome) step change from a regime in which parallel national procedures could run largely independently of one another. We will cover this in more detail in a forthcoming blog post on the impact of the Regulation on multi-jurisdictional transactions.
That said, the coordination framework has limits that practitioners should not overlook. While the 45-day Phase 1 timeline is now harmonised, the Regulation sets no binding EU-level deadline for Phase 2 (in-depth) investigations — their duration remains entirely within Member State discretion. For sensitive or politically significant transactions, this means review periods may remain materially longer and less predictable than the Phase 1 framework implies. Similarly, the single electronic filing portal, which would allow simultaneous submissions across participating Member States through one interface, will only become operational if at least nine Member States formally request it, and there is currently no public indication that this threshold will be met in the near term. The coordination obligation is therefore best understood as a best-efforts framework, not a guaranteed one-stop process.
A Commission opinion with teeth
The Commission’s opinion may now expressly propose mitigating measures, not merely identify risks or express concerns. This shifts the Commission’s role from purely advisory to something with a more directive character: Member States receiving such an opinion must give ‘due consideration’ to it — including any proposed mitigating measures — as part of their decision-making process.
The Member State in question will also be required to participate in a meeting to discuss the Commission’s opinion (if the Commission requests one) and provide written reasons, circulated within the cooperation mechanism, explaining how it took the opinion into account and, if it diverged, why. However, there is no obligation to adopt the Commission’s opinion. This is a significant retreat from the European Parliament’s original position, which would have empowered the Commission to adopt a binding decision authorising or prohibiting an investment outright. The outcome reflects the Council’s firm resistance to any transfer of sovereignty over national security decisions to the supranational level, a position that proved insurmountable across three rounds of trilogue negotiations. Therefore, while the Commission’s opinions will provide procedural accountability, the Commission will not have the muscle previously envisaged.
A new accountability mechanism for non-notified investments
The final text goes further still on non-notified investments. Where a host Member State receives comments from other Member States or an opinion from the Commission on a non-notified investment and decides not to screen, it must now organise a multilateral meeting if requested and provide a written explanation setting out its reasons — including any disagreement with the concerns raised and any alternative measures it intends to take. Previous iterations simply required the host Member State to inform commenting parties of its decision, and nothing more. The written explanation obligation is new, and its practical significance should not be underestimated: a Member State that wishes to waive through a sensitive investment despite active cross-border objection will now need to justify that choice in writing — a discipline that is likely to shape decision-making well before the formal process concludes.
Why the Rules Are Going Further: The Geopolitical Context
The final text adds a new objective clause: the Regulation exists to ensure foreign investments do not negatively affect security or public order in the Union, and Member States’ screening rules must align with that objective. The signal is deliberate — security protection, not investment facilitation, is at the heart of the framework.
The broadening of the FDI screening rules is part of a coherent EU strategy to protect its economic sovereignty in a more contested geopolitical environment. By mandating prior authorisation in sectors ranging from dual-use and defence to semiconductors and electoral infrastructure, the Regulation operationalises the principle that strategic dependencies represent security vulnerabilities that markets alone will not correct.
The Regulation is also just one layer of a broader regulatory stack the EU is assembling around strategic investment. The Commission’s proposed Industrial Accelerator Act (IAA), published on 4 March 2026, would add a parallel sector-specific regime operating alongside — not instead of — the FDI Screening Regulation, with the Commission having confirmed that both regimes require separate notification and approval procedures. The IAA targets investments exceeding €100 million in strategic manufacturing sectors, electric vehicles, batteries, solar photovoltaic technologies, and critical raw materials, but only where more than 40% of global manufacturing capacity in the relevant sector is controlled by a third country. Unlike the FDI Screening Regulation, which is security-based, the IAA explicitly introduces industrial-policy conditions: minimum EU workforce share, local R&D spend, technology transfer obligations, and local sourcing commitments. The legislative process is moving quickly: the Irish Presidency has made the IAA a Council priority, trilogues with the European Parliament are expected in Q4 2026 or Q1 2027, and a Parliament plenary vote is being targeted for December 2026.
The conditions framework for the IAA has already shifted in the Council. The Commission’s original proposal required investors to satisfy at least four of six specified conditions. The Council’s emerging position restructures this: one mandatory condition — a Union workforce share of at least 50% — plus at least three further conditions from the remaining list. The local sourcing commitment (30% of inputs from within the EU) has been softened to a ‘shall endeavour’ obligation rather than a hard requirement. The Council is also moving to introduce an explicit carve-out for subsidiaries of foreign investors and to dilute the Commission’s power to intervene directly in Member State investment authority reviews, an echo of the same sovereignty debate that shaped the final text of the FDI Screening Regulation.
The bigger picture for practitioners: there is now an emerging quartet of overlapping EU-level regimes, FDI screening, the IAA, the Foreign Subsidies Regulation (FSR), and merger control, each with distinct triggers that must be mapped from the outset of any transaction in a strategic sector. Greenfield investments, excluded from the FDI Screening Regulation’s mandatory scope, are widely expected to become the IAA’s central battleground: greenfield entry has become the preferred route for non-EU investors seeking to avoid M&A-based screening triggers.